Ji Yan-Yan, Zhang Shi-Xi, Kang Ye, Chen Song
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin 300020, China.
Tianjin Eye Hospital, Tianjin 300020, China.
Int J Ophthalmol. 2023 Jul 18;16(7):1034-1040. doi: 10.18240/ijo.2023.07.05. eCollection 2023.
To evaluate effects of endogenous dopamine induced by low concentration atropine eye drops on choroidal neovascularization (CNV) in high myopia mice.
The C57BL/6J mice were deprived of the right eye for 4wk, and the high myopia was diagnosed by optometry, the diopter was less than -6.00 D, and CNV was induced by 532 nm laser. The changes of dopamine D1 receptor (DRD1), dopamine D2 receptor (DRD2), and vascular endothelial growth factor A (VEGFA) were detected by Western blot technology at 0.5, 1, 2h, and 7d after 0.01%, 0.05%, and 0.1% atropine eye drops, respectively, the area of CNV was measured.
Significant increases were observed on the expression of DRD2 in mouse high myopia model at 0.5, 1, 2h, 7d with 0.05% and 0.1% atropine eye drops (<0.05). Significant decreases were observed on the expression of DRD1 and VEGFA in mouse high myopia model at 0.5, 1, 2h, 7d with 0.05% and 0.1% atropine eye drops (<0.05). The area of CNV induced by laser in the drug-treated group was significantly smaller than that in the control group, and the higher the concentration, the more significant the inhibitory effect (<0.05).
The 0.01%, 0.05%, 0.1% atropine eye drops can decrease the level of VEGFA and inhibit high myopia CNV indirectly by up-regulating the level of DRD2 and down-regulating the level of DRD1, and the effect of 0.05% and 0.1% atropine eye drops is more significant.
评估低浓度阿托品滴眼液诱导内源性多巴胺对高度近视小鼠脉络膜新生血管(CNV)的影响。
将C57BL/6J小鼠右眼剥夺4周,通过验光诊断为高度近视,屈光度小于-6.00D,并用532nm激光诱导CNV。分别于0.01%、0.05%和0.1%阿托品滴眼液滴眼后0.5、1、2小时及7天,采用蛋白质免疫印迹技术检测多巴胺D1受体(DRD1)、多巴胺D2受体(DRD2)和血管内皮生长因子A(VEGFA)的变化,测量CNV面积。
0.05%和0.1%阿托品滴眼液滴眼后0.5、1、2小时及7天,小鼠高度近视模型中DRD2表达显著增加(<0.05)。0.05%和0.1%阿托品滴眼液滴眼后0.5、1、2小时及7天,小鼠高度近视模型中DRD1和VEGFA表达显著降低(<0.05)。药物治疗组激光诱导的CNV面积显著小于对照组,浓度越高,抑制作用越显著(<0.05)。
0.01%、0.05%、0.1%阿托品滴眼液可通过上调DRD2水平和下调DRD1水平降低VEGFA水平,间接抑制高度近视CNV,0.05%和0.1%阿托品滴眼液效果更显著。